-

12:43:50 PM

ABVC Stock News

ABVC - ABVC BioPharma Inc

05/25/22 8:30 AM

Nasdaq : ABVC

low float

ABVC BioPharma Engaged by Orion BioTech to Identify Global Licensing Partners

via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that it has been engaged by Orion BioTech, Inc., a

RHEA-AI

neutral

05/23/22 7:30 AM

Nasdaq : ABVC

low float

Prestigious Researchers to Provide Consulting Services in Connection with ABVC BioPharma's Depression Medicines

ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that Dr. Maurizio Fava and Dr. Thomas Laughren have

RHEA-AI

neutral

05/16/22 5:46 PM

Nasdaq : ABVC

low float

ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results

ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced its financial and operating results for the first

RHEA-AI

very positive

05/16/22 3:25 PM

Nasdaq : ABVC

offeringlow float

WallachBeth Capital Announces Completion of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced the completion of the purchase and sale of 2,000,000 shares of common stock of ABVC BioPharma, Inc. (Nasdaq: ABVC), and warrants to

RHEA-AI

neutral

05/13/22 8:30 AM

Nasdaq : ABVC

low float

ABVC BioPharma Engages the FreeMind Group to Support Grant Funding

via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has engaged the FreeMind Group to help ABVC explore

RHEA-AI

very positive

05/12/22 9:00 AM

Nasdaq : ABVC

offeringlow float

WallachBeth Capital Announces Pricing of ABVC BioPharma, Inc. (Nasdaq: ABVC) $4.22 Million Registered Direct Offering

WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced that ABVC BioPharma, Inc. (Nasdaq: ABVC), a clinical-stage biopharmaceutical company, has entered into securities purchase agreements with

RHEA-AI

neutral

05/12/22 8:30 AM

Nasdaq : ABVC

offeringlow float

ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering

ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC) today announced that it has entered into securities purchase agreements with certain institutional investors for the issuance and sale of 2,000,000 shares of common

RHEA-AI

neutral

05/10/22 8:30 AM

Nasdaq : ABVC

clinical triallow float

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated

via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the first subject began treatment at the Cheng

RHEA-AI

neutral

05/05/22 8:30 AM

Nasdaq : ABVC

low float

ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process

ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that

RHEA-AI

very positive

05/03/22 8:30 AM

Nasdaq : ABVC

low float

ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed

via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that BioKey, a wholly-owned subsidiary of the company

RHEA-AI

very positive